MX2021011760A - Metodos para el tratamiento de canceres usando antisentido. - Google Patents

Metodos para el tratamiento de canceres usando antisentido.

Info

Publication number
MX2021011760A
MX2021011760A MX2021011760A MX2021011760A MX2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A
Authority
MX
Mexico
Prior art keywords
methods
antisense
igf
insulin
compositions
Prior art date
Application number
MX2021011760A
Other languages
English (en)
Spanish (es)
Inventor
Douglas C Hooper
David W Andrews
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2021011760A publication Critical patent/MX2021011760A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2021011760A 2019-03-28 2020-03-27 Metodos para el tratamiento de canceres usando antisentido. MX2021011760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825516P 2019-03-28 2019-03-28
PCT/US2020/025217 WO2020198587A1 (en) 2019-03-28 2020-03-27 Methods for treating cancers using antisense

Publications (1)

Publication Number Publication Date
MX2021011760A true MX2021011760A (es) 2021-12-10

Family

ID=72609134

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011760A MX2021011760A (es) 2019-03-28 2020-03-27 Metodos para el tratamiento de canceres usando antisentido.

Country Status (7)

Country Link
US (1) US20220195440A1 (https=)
EP (1) EP3946287A4 (https=)
JP (2) JP2022527473A (https=)
AU (1) AU2020244865A1 (https=)
CA (1) CA3134969A1 (https=)
MX (1) MX2021011760A (https=)
WO (1) WO2020198587A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
EA201992485A1 (ru) 2017-04-19 2020-02-17 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования stat3
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541036B1 (en) * 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
WO2002027019A1 (en) * 2000-09-29 2002-04-04 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
NZ554831A (en) * 2004-11-09 2009-10-30 Schering Corp Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
EP1900825A1 (en) * 2006-09-13 2008-03-19 Rheinische Friedrich-Wilhelms-Universität Bonn Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2016164916A1 (en) * 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
US10357509B2 (en) * 2017-03-09 2019-07-23 Thomas Jefferson University Methods and compositions for treating cancers using antisense

Also Published As

Publication number Publication date
AU2020244865A1 (en) 2021-10-21
US20220195440A1 (en) 2022-06-23
CA3134969A1 (en) 2020-10-01
EP3946287A1 (en) 2022-02-09
WO2020198587A1 (en) 2020-10-01
JP2025098027A (ja) 2025-07-01
JP2022527473A (ja) 2022-06-02
EP3946287A4 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
MX2019010725A (es) Metodos y composiciones para tratar canceres usando antisentido.
MX2021011760A (es) Metodos para el tratamiento de canceres usando antisentido.
Zecha et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations
RU2017126610A (ru) Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
JP2015516496A5 (https=)
US20180110978A1 (en) Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields
RU2014150569A (ru) Конъюгат фотосенсибилизатора и хитозана и его применение
ES2746276T3 (es) Un aparato para controlar una sonda láser
MX2020010676A (es) Derivados de pladeniolida como agentes dirigidos al espliceosoma para tratar el cancer.
EA201100626A1 (ru) Лечение рака с помощью ионизирующего облучения и иммуноцитокинов
MX2021005169A (es) Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.
MX2021005168A (es) Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.
Deng et al. Organic light-emitting diode therapy promotes longevity through the upregulation of SIRT1 in senescence-accelerated mouse prone 8 mice
US20210283255A1 (en) Reducing Damage From Chemotherapy And Increasing Cancer Kill Rates By Using Interweaved Low Dose Radiation
CN114099975B (zh) 一种胃部滞留胶囊、腰带及胃部神经刺激的方法
Tong et al. Inhibiting human breast Cancer cells (MCF-7) with alternating Micro-current at intermediate frequency (ACIF) in vitro and in vivo
RU2739196C2 (ru) Способ инициации гибели опухолевых клеток янтарной кислотой и ВЧ- и СВЧ-энергией волнового излучения
RU2606834C2 (ru) Гель-фотосенсибилизатор для фотодинамической терапии
KR101666838B1 (ko) 흉터 치료 시스템
RU2325200C2 (ru) Способ лазерного подавления роста и элиминации злокачественных образований
Carroll Photobiomodulation literature watch November 2021
von Hardenberg et al. Therapeutic in vivo and in vitro effects of argon dye laser and hematoporphyrin derivative in lung cancer
RU2819734C2 (ru) Излучение внутриопухолевого альфа-излучателя и активация цитоплазматических рецепторов к внутриклеточному патогену
Mao Stem cells as a photosensitizer carrier to attack cancer cells for photodynamic therapy of breast cancer
Matera et al. Photoswitchable molecular prosthetics to photocontrol auditory neurons